Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more
Lipigon Pharmaceuticals AB (LPGO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.552x
Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has a cash flow conversion efficiency ratio of -0.552x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.32 Million) by net assets (Skr15.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lipigon Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Lipigon Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lipigon Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TERADATA
BE:3T4
|
0.616x |
|
Danske Invest Fjernosten
CO:DKIFJIX
|
N/A |
|
UCB-P-I
NASDAQ:UCB-P-I
|
N/A |
|
GAS NATURAL SDG
BE:GAN
|
0.043x |
|
ANGLO AMERICAN (NGLB.SG)
STU:NGLB
|
0.053x |
|
Jahwa Electronics Co. Ltd.
KQ:033240
|
N/A |
|
26U
F:26U
|
N/A |
|
Ellen AB (publ)
ST:ELN
|
-0.130x |
Annual Cash Flow Conversion Efficiency for Lipigon Pharmaceuticals AB (2018–2024)
The table below shows the annual cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr7.76 Million | Skr-24.78 Million | -3.193x | -534.28% |
| 2023-12-31 | Skr28.44 Million | Skr-14.32 Million | -0.503x | +94.80% |
| 2022-12-31 | Skr3.87 Million | Skr-37.47 Million | -9.679x | -529.59% |
| 2021-12-31 | Skr22.96 Million | Skr-35.30 Million | -1.537x | -131.41% |
| 2020-12-31 | Skr12.98 Million | Skr-8.62 Million | -0.664x | +74.08% |
| 2019-12-31 | Skr2.17 Million | Skr-5.56 Million | -2.563x | -166.14% |
| 2018-12-31 | Skr-842.00K | Skr-3.26 Million | 3.875x | -- |